US2018171401A1PendingUtilityA1
Methods for obtaining a sequence
Assignee: UNIV LELAND STANFORD JUNIORPriority: Sep 9, 2011Filed: Jul 31, 2017Published: Jun 21, 2018
Est. expirySep 9, 2031(~5.1 yrs left)· nominal 20-yr term from priority
C12Q 1/6869C12Q 2535/122C12Q 1/6874C12Q 1/6806C12Q 2527/146C12Q 1/6855B01L 3/5027Y02A50/30
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention generally relates to methods for obtaining a sequence, such as a consensus sequence or a haplotype sequence. In certain embodiments, methods of the invention involve determining an amount of amplifiable nucleic acid present in a sample, partitioning the nucleic acid based upon results of the determining step such that each partitioned portion includes, on average, a subset of unique sequences, sequencing the nucleic acid to obtain sequence reads, and assembling a consensus sequence from the reads.
Claims
exact text as granted — not AI-modified1 .- 20 . (canceled)
21 . A kit for sequencing DNA fragments having blunt ends, comprising
PCR amplification adapters configured to blunt end ligate to the DNA fragments; quantitative PCR primers with homology to the PCR amplification adapters for quantitatively amplifying the DNA fragments; a transposase enzyme and a plurality of transposon end complexes configured to cleave the DNA fragments into size-selected DNA fragments; and a plurality of barcode sequences configured to be incorporated into the size-selected DNA fragments upon amplification, wherein each barcode sequence has at least two mismatches from every other barcode sequence in the plurality of barcode sequences.
22 . The kit of claim 21 , wherein the PCR amplification adapters have a nucleotide sequence of SEQ ID NOs: 1, 2, 3, or 4.
23 . The kit of claim 21 , wherein the quantitative PCR primers have a nucleotide sequence of SEQ ID NOs: 5 or 6.
24 . The kit of claim 21 , wherein the transposase enzyme is a TN-5 transposase enzyme.
25 . The kit of claim 21 , wherein the barcode sequences are part of the transposon end complexes configured to cleave the DNA fragments.
26 . The kit of claim 21 , wherein the barcode sequences have no homopolymer regions.
27 . The kit of claim 21 , wherein the bar code sequences are from about 5 nucleotides to about 15 nucleotides in length.
28 . The kit of claim 21 , where in the bar code sequences are from about 4 nucleotides to about 7 nucleotides in length.
29 . The kit of claim 21 , further comprising a ligase for ligating the barcode sequences to the size-selected DNA fragments.
30 . The kit of claim 29 , wherein the ligase is a blunt-end ligase.
31 . The kit of claim 21 , further comprising gel material for producing a gel to size-select the cleaved DNA fragments.
32 . The kit of claim 21 , further comprising DNA capture beads for purifying the DNA fragments.
33 . The kit of claim 32 , wherein the DNA capture beads comprise streptavidin-coated beads.
34 . The kit of claim 21 , further comprising an amplification enzyme.
35 . The kit of claim 34 , wherein the amplification enzyme is Taq DNA polymerase.
36 . The kit of claim 21 , wherein the barcode sequences are part of an adapter that further comprises sequencing primer annealing sequences.
37 . The kit of claim 21 , wherein the PCR amplification adaptors comprise a barcode sequence to identify amplified DNA fragments.
38 . The kit of claim 37 , wherein the PCR amplification adaptors comprise the same barcode sequence such that the same barcode is attached to both sides of an amplified DNA fragment.
39 . The kit of claim 21 , wherein the quantitative PCR primers comprise at least one fluorescent dye.
40 . The kit of claim 39 , wherein the quantitative PCR primers comprise at least one fluorescent dye and one quenching dye.Join the waitlist — get patent alerts
Track US2018171401A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.